Clinical efficacy of paliperidone in treatment of first episode schizophrenia

Objective To investigate the clinical efficacy and safety of paliperidone in treatment of first episode schizophrenia.Methods The data of 76 cases of patients with schizophrenia from January 2012 to June 2012 in our hospital were collected.The patients were randomly divided to paliperidone group and risperidone group,38 cases per group,were observed for 8 weeks.We used positive and negative symptoms scale (PANSS),personal and social function scale (PSP) to assess clinical efficacy and social function,used treatment emergent symptom scale(TESS) to evaluate adverse reactions.Results All of 72 patients finished the follow up,35 cases in paliperidone group,37 cases in risperidone groups.After 4 weeks,score-reducing rate of PANSS in paliperidone group were all the more obvious,there was significant difference in two groups (P 0.05).After 8 weeks,aggregate score of PANSS,points of positive symptoms,points of negative symptoms and points of general psychiatric symptoms were obviously decreased as compared with that before treatment in two groups(P0.01).The effective rates were 82.9% and 86.5%,in paliperidone group and risperdal group (P0.05);After 8 weeks,PSP value increased in two groups,paliperidone group was more apparent (P0.05).There were no serious adverse reactions in both groups.Conclusion There are no obvious difference between paliperidone and risperidone in treatment of first episode schizophrenia,but paliperidone have the effect to fast,high safety features,and effectively improve the social function